Acacia19 Aug 2020 08:27
The Company will continue to assess further hospital opportunities to utilize its US sales and marketing infrastructure, including in-licensing or acquiring complementary product candidates, as it did with BYFAVO, which it in-licensed from Cosmo Pharmaceuticals in January 2020.